ClinicalTrials.gg
RecruitingNCT07190833Updated Nov 4, 2026

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

A Phase 1 interventional study of OTS-412 and Hydroxyurea (HU) in Treatment-Refractory Solid Tumors, sponsored by Bionoxx Inc.. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Bionoxx Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 4, 2026Enrollment updatedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

Read the detailed description

The primary objective of this study is:

  • to evaluate the safety of OTS-412 monotherapy, combination therapy of OTS-412 and hydroxyurea, or combination therapy of OTS-412, hydroxyurea, and atezolizumab
  • to find an optimal dosage of hydroxyurea when used in combination with OTS 412. Hydroxyurea is currently used at dosages of 15-35 mg/kg/day for certain conditions, and the optimal dosage when combined with the oncolytic virus will be determined within this range.
  • to find an optimal dosage of OTS-412 when used in combined with hydroxyurea and atezolizumab.

The secondary objectives include evaluating anti-tumor effects, immune responses, and pharmacokinetics (PK) of OTS-412 in blood over time after administration.

This study focuses on various solid tumors that are resistant to standard therapies, particularly immune checkpoint inhibitors alone or in combination with other therapies.

02

Conditions studied

  • Treatment-Refractory Solid Tumors

Keywords

  • Oncolytic vaccinia virus
03

In context

Lead sponsor

Bionoxx Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 years of age or older
  2. Diagnosed with a malignant solid tumor via histology or cytology, although a radiological diagnosis is permissible for hepatocellular carcinoma
  3. Solid tumors that demonstrate limited response or resistant to SOC therapy, particularly when atezolizumab or other inhibitors, or PD-1 inhibitors are administered as monotherapy or in combination therapy. This may include, but not limited to, hepatocellular carcinoma, melanoma, renal cell carcinoma, urothelial carcinoma, biliary cancer, head and neck cancer, gastric cancer, breast cancer, colorectal cancer, and any solid tumor with microsatellite instability (MSI)-high status. At minimum, SOC treatment presented in the Protocol should have been received for each cancer type.
  4. Patients with tumors that have known actionable molecular alterations (i.e. EGFR, ALK, BRAF, etc) must have progressed on targeted therapy.
  5. Lesions that are deemed feasible for injection either directly (palpable subcutaneous tumors) or under ultrasound guidance (deep-seated tumors). Additionally, tumor(s) should not be adjacent or encasing vital structures such as major nerves or blood vessels, pericardium, gastrointestinal tract or other hollow organs, mucosal regions or spinal cord that could cause occlusion or compression in case of tumor swelling or erosion and major bleeding in the case of necrosis.
  6. At least one measurable (longest diameter, LD ≥1 cm) and injectable tumor that has not been previously received local treatment on computed tomography (CT) or magnetic resonance imaging (MRI)
  7. The total volume of injectable tumor(s) should be 2 cm3 or more in 1x10E8 pfu dosing cohorts and 6 cm3 or more in 3x10E8 pfu dosing cohorts.
  8. of 12 weeks or more
  9. (ECOG) performance status is 0, 1, or 2
  10. Adequate pulmonary function, such as baseline pulse oximetry of at least 92% on room air
  11. Laboratory test results meet the following:

    • ≥ 1,500 /μL
    • White blood cell (WBC) ≥ 2,500 /μL
    • (Hb) ≥ 9.0 g/dL without packed red blood cell transfusion within the prior 2 weeks
    • ≥ 75,000 /μL without platelet transfusion
    • and ALT ≤ 5 ×
    • Total ≤ 1.5 × ULN
    • ≥ 60 mL/minute (measured using Cockcroft-Gault formula).
    • LDH ≤ 3 × ULN
    • or aPTT ≤ 1.5 × ULN.
  12. Voluntarily decided to participate in this clinical study and provided written consent

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received talimogene laherparepvec (Imlygic) or any other oncolytic virus, have received any systemic or local anti-cancer therapy for tumors within 4 weeks prior to the first administration of the study drugs(C1D1), or have not recovered from the adverse events due to these therapies to at least Grade 1 severity or returned to baseline levels prior to C1D1, with the exceptions of any grade of alopecia and Grade 2 neuropathy.
  2. Patients who have untreated symptomatic , have treated brain metastases without evidence of stability or improvement on two scans at least two weeks apart, have regardless of treatment, or have received anti-convulsants within the last 28 days.
  3. Tumors adjacent to vital neurovascular structures or at risk of airway compromise in the event of post injection tumor swelling, bleeding, or inflammation. Patients with tumors near vital structures can be enrolled as long as they have other lesions that are appropriate for injection (these tumors near vital structures will not be injected).
  4. History of other that developed within 5 years (However, cervical carcinoma in situ, basal cell carcinoma, or squamous cell skin cancer, and all cancers after 5 years since it was cured are acceptable.)
  5. History of organ transplant surgery
  6. Known significant immunodeficiency due to underlying illness (e.g., /AIDS) and/or immune-suppressive medication including high-dose systemic (prednisone 20 mg/day or equivalent which is ongoing and/or was taken more than 4 weeks within the preceding 2 months of study treatment)
  7. History of or active disease
  8. Ongoing severe inflammatory skin disease (as determined by the Investigator) requiring medical treatment or history of severe eczema (as determined by the Investigator) requiring prior medical treatment
  9. Anticoagulation or anti- medication that cannot be withheld for the required period prior to and after the OTS-412 injection, specifically:

    • Coumadin for 7 days
    • Direct Factor Xa inhibitor (rivaroxaban, apixaban, edoxaban) for 4 days
    • Oral direct thrombin inhibitor (dabigatran) for 4 days
    • Aspirin, clopidogrel, ticagrelor for 7 days
    • Prasugrel for 9 days
    • Low molecular weight heparin for 24 hours
    • Unfractionated heparin for 12 hours Please contact the Sponsor for questions regarding the management of other antithrombotic agents prior to treatment.
  10. Taking antiviral drugs (immunoglobulin, interferon, etc.) or being unable to discontinue these medications at least 7 days prior to receiving the study drugs (note that oral antiviral drugs for and C are allowed).
  11. Severe medical conditions, as determined by the Investigator, that may increase the patient's susceptibility to adverse medical risks during or after OTS-412 treatment, such as volume loading, tachycardia, or hypotension.
  12. Current or history of significant cardiovascular disease, including significant coronary artery disease (e.g., requiring angioplasty or stent), congestive heart failure within the preceding 12 months, myocardial infarction, ischemic cardiomyopathy, or myocarditis, unless cardiology consultation and clearance have been obtained for study participation
  13. History of the side effects of past smallpox vaccinations
  14. History of the or severe/serious AEs to the components of the study drugs
  15. Unable to receiving a contrast medium for a radiological scan due to a history of allergy to iodide contrast agents
  16. Vaccination with within 4 weeks before the first administration of the study drugs
  17. Receiving an product within 4 weeks prior to the first administration of the study drugs
  18. Pregnant or breastfeeding women
  19. Patient who does not consent to the use of appropriate methods for at least 6 months, when the woman is of childbearing age, or at least 1 year, when the male patient's spouse is a woman of childbearing age, after the last administration of the study drugs
  20. Other medical condition that in the judgement of the Investigator may increase the risk associated with study participation or may interfere with interpretation of study results and/or otherwise make the patient inappropriate for study participation
  21. Patient unable or unwilling to comply with the protocol
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    OTS412 1 \* 10E8 pfu

    Drug: OTS-412

  • Experimental
    Cohort 2

    OTS412 1 \* 10E8 pfu + HU 15mg/kg/day

    Drug: OTS-412 · Drug: Hydroxyurea (HU)

  • Experimental
    Cohort 3

    OTS412 1 \* 10E8 pfu + HU 25mg/kg/day

    Drug: OTS-412 · Drug: Hydroxyurea (HU)

  • Experimental
    Cohort 4

    OTS412 1 \* 10E8 pfu + HU 35mg/kg/day

    Drug: OTS-412 · Drug: Hydroxyurea (HU)

  • Experimental
    Cohort 5

    OTS412 1 \* 10E8 pfu + HU optimal dose + Atezolizumab 1200mg

    Drug: OTS-412 · Drug: Hydroxyurea (HU) · Drug: Atezolizumab

  • Experimental
    Cohort 6

    OTS412 3 \* 10E8 pfu + HU optimal dose + Atezolizumab 1200mg

    Drug: Hydroxyurea (HU) · Drug: Atezolizumab · Drug: OTS-412

  • Experimental
    Expansion cohort

    OTS412 optimal dose + HU optimal dose + Atezolizumab 1200mg

    Drug: Hydroxyurea (HU) · Drug: Atezolizumab · Drug: OTS-412

Interventions

06

What researchers measure

Primary outcomes

  1. RP2D of OTS-412 and HU combination with Atezolizumab

    Overall assessment of safety, tolerability, dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and available pharmacokinetic (PK), pharmacodynamic (PD), and preliminary antitumor activity data collected during the dose-escalation phase.

    Time frame: Up to approximately 28 days after the last subject in each cohort completes the DLT evaluation period.

  2. Incidence and severity of adverse events (AEs)

    National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 or higher in OTS 412, OTS-412/HU combination, and OTS 412/HU/atezolizumab combination treatment

    Time frame: From enrollment to 180 days after the last dose of the study drugs.

Secondary outcomes

  1. Tumor response

    Determined by the Investigator according to RECIST v1.1 (or mRECIST for hepatocellular carcinoma) and/or iRECIST

    Time frame: From enrollment to 28 days after the last dose of the study drugs

  2. Overall survival

    Defined as time from the study drug initiation to death from any cause

    Time frame: Defined as time from the study drug initiation to death from any cause

  3. PK analysis

    Assessment of the concentration of OTS-412 genomic particles (qPCR) in blood over time

    Time frame: From enrollment to Day 22

  4. Firefly Luciferase Activity-Based Immune Monitoring

    1. Rate of patients to achieve target absolute neutrophil count (ANC) level (between 1500 and 3000/μL) 2. Changes in ANC over time 3. Changes in lymphocytes count over time 4. Changes in immunophenotype of lymphocytes over time 5. Changes in serum cytokines (including but not limited to IL-1β, IL-6, INF-γ, TNF-α) over time

    Time frame: 1. 7 days after OTS-412 administration 2. From enrollment to 180 days after the last dose of the study drugs. 3. From enrollment to 180 days after the last dose of the study drugs. 4. From enrollment to Day 22 5. From enrollment to Day 22

  5. Firefly Luciferase Activity-Based Immune Monitoring

    Assessment of tumor tissue histology and immunology, including immunological assays for T cells and programmed cell death ligand 1 (PD-L1) expression (optional) Neutralizing antibody measurement against OTS-412 Firefly luciferase (FLuc) T cell response assessment

    Time frame: From enrollment to Day 22

Other outcomes

  1. Changes in activated neutrophils (aN) and activated T lymphocytes (aT) assessed by FLuc activity in isolated neutrophils and T lymphocytes over time

    Time frame: From enrollment to Day 22

  2. Objective tumor response

    According to RECIST v1.1 and/or iRECIST criteria based on radiologic evaluations

    Time frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)

  3. Tumor response / Response patterns by injected vs non-injected lesions

    By comparing changes in tumor size and lesions from baseline and evaluating objective responses over time

    Time frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 24, 2025
StartActual
Mar 9, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
27→21
Nov 4, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedRP2D of OTS-412 and HU combination with AtezolizumabTime frame: Up to approximately 28 days after the last subject in each cohort completes the DLT evaluation period.
  • AddedIncidence and severity of adverse events (AEs)Time frame: From enrollment to 180 days after the last dose of the study drugs.
  • RemovedIncidence and severity of adverse events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 or higher in OTS 412, OTS-412/HU combination, and OTS 412/HU/atezolizumab combination treatmentTime frame: From enrollment to 180 days after the last dose of the study drugs.
Nov 4, 2026
Secondary outcomes
1 edited, 6 added, 14 removed
What changed in the outcomes
  • AddedTumor responseTime frame: From enrollment to 28 days after the last dose of the study drugs
  • AddedOverall survivalTime frame: Defined as time from the study drug initiation to death from any cause
  • AddedPK analysisTime frame: From enrollment to Day 22
  • AddedFirefly Luciferase Activity-Based Immune MonitoringTime frame: 1. 7 days after OTS-412 administration 2. From enrollment to 180 days after the last dose of the study drugs. 3. From enrollment to 180 days after the last dose of the study drugs. 4. From enrollment to Day 22 5. From enrollment to Day 22
  • AddedFirefly Luciferase Activity-Based Immune MonitoringTime frame: From enrollment to Day 22
  • RemovedTumor response, as determined by the Investigator according to RECIST v1.1 (or mRECIST for hepatocellular carcinoma) and/or iRECISTTime frame: From enrollment to 28 days after the last dose of the study drugs
  • RemovedOverall survival defined as time from the study drug initiation to death from any causeTime frame: From enrollment up to 15 years after end of study
  • RemovedPK analysis: Assessment of the concentration of OTS-412 genomic particles (qPCR) in blood over timeTime frame: From enrollment to Day 22
  • RemovedRate of patients to achieve target absolute neutrophil count (ANC) level (between 1500 and 3000/μL) 7 days after OTS-412 administrationTime frame: 7 days after OTS-412 administration
  • RemovedChanges in ANC over timeTime frame: From enrollment to 180 days after the last dose of the study drugs.
  • RemovedChanges in lymphocytes count over timeTime frame: From enrollment to 180 days after the last dose of the study drugs.
  • RemovedChanges in immunophenotype of lymphocytes over timeTime frame: From enrollment to Day 22
  • RemovedChanges in serum cytokines (including but not limited to IL-1β, IL-6, INF-γ, TNF-α) over timeTime frame: From enrollment to Day 22
  • RemovedAssessment of tumor tissue histology and immunology, including immunological assays for T cells and programmed cell death ligand 1 (PD-L1) expression (optional)Time frame: From enrollment to Day 22(exceptionally, for Cohort 1, 28 days after last study drug administration)
  • RemovedViral shedding analysis: Assessment of the presence of the virus in oral and urine samplesTime frame: From enrollment to Day 22
  • RemovedNeutralizing antibody measurement against OTS-412Time frame: From enrollment to Day 22
  • RemovedFirefly luciferase (FLuc) T cell response assessmentTime frame: From enrollment to Day 22
  • Editedother outcomeTumor response / Response patterns by injected vs non-injected lesionsTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
  • Addedother outcomeObjective tumor responseTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
  • Removedother outcomeObjective tumor response based on RECIST v1.1 and/or iRECISTTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
  • Removedother outcomeAnalysis of response patterns by injected vs non-injected lesionsTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
Nov 4, 2026
Contact
Study contact changed: d•••@bionoxx.com · •••7457→k•••@bionoxx.com · •••7457; added d•••@bionoxx.com. See the current contact
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Enrollment 27→21
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedRP2D of OTS-412 and HU combination with AtezolizumabTime frame: Up to approximately 28 days after the last subject in each cohort completes the DLT evaluation period.
    • AddedIncidence and severity of adverse events (AEs)Time frame: From enrollment to 180 days after the last dose of the study drugs.
    • RemovedIncidence and severity of adverse events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 or higher in OTS 412, OTS-412/HU combination, and OTS 412/HU/atezolizumab combination treatmentTime frame: From enrollment to 180 days after the last dose of the study drugs.
    Secondary outcomes 1 edited, 6 added, 14 removed
    What changed in the outcomes
    • AddedTumor responseTime frame: From enrollment to 28 days after the last dose of the study drugs
    • AddedOverall survivalTime frame: Defined as time from the study drug initiation to death from any cause
    • AddedPK analysisTime frame: From enrollment to Day 22
    • AddedFirefly Luciferase Activity-Based Immune MonitoringTime frame: 1. 7 days after OTS-412 administration 2. From enrollment to 180 days after the last dose of the study drugs. 3. From enrollment to 180 days after the last dose of the study drugs. 4. From enrollment to Day 22 5. From enrollment to Day 22
    • AddedFirefly Luciferase Activity-Based Immune MonitoringTime frame: From enrollment to Day 22
    • RemovedTumor response, as determined by the Investigator according to RECIST v1.1 (or mRECIST for hepatocellular carcinoma) and/or iRECISTTime frame: From enrollment to 28 days after the last dose of the study drugs
    • RemovedOverall survival defined as time from the study drug initiation to death from any causeTime frame: From enrollment up to 15 years after end of study
    • RemovedPK analysis: Assessment of the concentration of OTS-412 genomic particles (qPCR) in blood over timeTime frame: From enrollment to Day 22
    • RemovedRate of patients to achieve target absolute neutrophil count (ANC) level (between 1500 and 3000/μL) 7 days after OTS-412 administrationTime frame: 7 days after OTS-412 administration
    • RemovedChanges in ANC over timeTime frame: From enrollment to 180 days after the last dose of the study drugs.
    • RemovedChanges in lymphocytes count over timeTime frame: From enrollment to 180 days after the last dose of the study drugs.
    • RemovedChanges in immunophenotype of lymphocytes over timeTime frame: From enrollment to Day 22
    • RemovedChanges in serum cytokines (including but not limited to IL-1β, IL-6, INF-γ, TNF-α) over timeTime frame: From enrollment to Day 22
    • RemovedAssessment of tumor tissue histology and immunology, including immunological assays for T cells and programmed cell death ligand 1 (PD-L1) expression (optional)Time frame: From enrollment to Day 22(exceptionally, for Cohort 1, 28 days after last study drug administration)
    • RemovedViral shedding analysis: Assessment of the presence of the virus in oral and urine samplesTime frame: From enrollment to Day 22
    • RemovedNeutralizing antibody measurement against OTS-412Time frame: From enrollment to Day 22
    • RemovedFirefly luciferase (FLuc) T cell response assessmentTime frame: From enrollment to Day 22
    • Editedother outcomeTumor response / Response patterns by injected vs non-injected lesionsTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
    • Addedother outcomeObjective tumor responseTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
    • Removedother outcomeObjective tumor response based on RECIST v1.1 and/or iRECISTTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
    • Removedother outcomeAnalysis of response patterns by injected vs non-injected lesionsTime frame: From enrollment to Day 43(exceptionally, for Cohort 1, 28 days after last study drug administration)
    Contact Study contact changed: d•••@bionoxx.com · •••7457→k•••@bionoxx.com · •••7457; added d•••@bionoxx.com. See the current contact
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07190833
Lead sponsor
Bionoxx Inc.
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Mar 9, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

KyungMi Min, Project Manager
Contact
kmmin@bionoxx.com
+82-55-367-7457
Dohyun Shin
Contact
dhshin@bionoxx.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OTS-412

Start the discussion